Login to Your Account

Regeneron Extends Vision for VEGF Drug to DME

By Catherine Shaffer

Monday, April 11, 2011
Two months after submitting a U.S. Biologics License Application for VEGF Trap-Eye (afilbercept ophthalmic solution) in wet age-related macular degeneration, Regeneron Pharmaceuticals Inc. and Bayer HealthCare began Phase III trials in a new indication, diabetic macular edema (DME).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription